Member Info for Richob

I meant the nutjob not you.

And such an informative post from yourself as per usual.

Fair comment runner.

Didn't hear NDA but did hear "collaboration with governments" and "desire for sovereign based tests".

Happy with that.

All the best.

He's basically saying the previous (Innova) tests weren't good enough but did identify a proportion of cases.

Just need one that works well then.

All the best

Well said, Zoom,

The sp goes down a couple of pence and the recent 18% uplift is suddenly forgotten.

Over the last couple of days, we have seen relatively smaller sells and larger buys in the mix.

As an example, yesterday's first hour saw selling and the the two 90k delayed publication buys that came up after 430 were both actually made around about 915am.

It seems that "larger" buyers are taking a position at the expense of us smaller investors (just a view as I have no idea who has what). Whilst I would love to be a "larger" buyer, I won't be letting my shares be part of a "2p panic drop fire sale" and will add in smaller amounts as and when the pension allows.

It seems that LFTs are back in vogue and clearly would have helped against the recent virus surge in identifying carriers earlier.

Come on Alistair, you have kept us waiting this long on this aspect of the business, so get into the mix.

((Other aspects (CTA filing and collaborations) deserve a well done.))

All the best.

Cave Exigo

Unless I have misheard this, we are planning 2.5 million jabs per week and are ramping up to that number.

For a UK population of just under 80 million, I think that takes 32 weeks. However, this assumes one dose and we are told that two doses are required and the plan doesn't appear to take this into account.

Not knocking, just wondering if this is a reasonable question and if any mathematicians out there can factor in say a twelve week gap between doses?

Or is this why tighter rules look like they may be incoming?

On a more relevant note, good to see the late delayed buys accounting for more than the afternoon sells.

Come on Alistair.

All the best.

Marc Hummersome at Astrea has just joined them from Cytiva. Interesting that the recent deal appears at this point.

All the best.

I wasn't sure anybody would get it. Thanks.

Surescreen*

https://www.gov.uk/government/news/government-to-deploy-first-british-manufactured-rapid-lateral-flow-antigen-tests-for-covid-19

Obviously good for Widescreen but not bad at all for:

Testing
LFTs
Antigen tests

I think it says UK companies (plural).

Cave Exigo

Just a new thread given the fight back.

workthere. You told us last year that you worked at Avacta when the sp was lower than it is today.

Why don't you go and buy Alistair a coffee and see if he is writing an RNS?

For others. There is plenty of buying today so I think we are just getting the roller coaster treatment from the MMs, which isn't unexpected really.

All the best.

Is it still Monday?

Potentially far more to the POINT RNS than meets the eye it would appear.

Avacta doesn't hide what it is seeking to do.

"Shaping the future of cancer treatment with powerful therapeutic and diagnostic platforms" with three current goals:

Developing next generation cancer therapies.

Affimer C19 diagnostic tests

Diagnostic reagent and assay development

The first one has had the recent CTA filing which has attracted the attention of POINT at the very least.

The second one is the current focus of many investors and is either about to burst onto the scene or not.

The third has progressed with ELISA and it looks like Adeptrix have at least one assay kit with an affimer involved.

Given the new refocus on lateral flow tests and the size of the world, you'd think we'd be in with a shout. My opinion obviously.

All the best.

Criticism is fine O and W but please keep it accurate within your very limited and usually negative postings.

Where does zero revenue come from for example?

As regards leewill, he has been a top poster on here for many months and provides great research as opposed to supposed "warnings" from those with their own agenda.

Anybody clicking on you and leewill can make their own mind up.

All the best.

https://avacta.com/about/ip/

This assay has an Affimer in it under product details. Apologies if previously posted.

https://www.adeptrix.com/store#!/SARS-CoV-2-S1-Glycoprotein-Assay/p/234586062

This seems to indicate that the recent collaboration follows on from the CTA filing, so perhaps others to follow:

https://www.pbiforum.net/mag/featured/avacta-enters-license-agreement-with-point-biopharma/